Ligand Pharmaceuticals Director John Kozarich Sells 934 Shares at $125/Share.

Ligand Pharmaceuticals Inc. (LGND) has announced that Director John W. Kozarich has sold 934 shares at a price of $125 per share on July 10, 2025.

Ligand Pharmaceuticals Inc. (LGND) has announced that Director John W. Kozarich sold 934 shares at a price of $125 per share on July 10, 2025. The sale, which occurred through UBS Financial Services, Inc., represents a minimal portion of the company's outstanding shares, approximately 0.0048% of the total 19,294,168 shares outstanding. The shares were originally acquired by Kozarich in separate transactions on June 6, 2019, and June 4, 2021, directly from the issuer.

The transaction is notable as it follows a Form 144 filing, which indicates a planned disposition of common shares. The filing, submitted on July 2, 2025, provides details about the sale, including the number of shares, the aggregate market value, and the expected sale date. The filing also states that no other sales were reported for the past three months, and no material adverse information was acknowledged by the filer as required under Rule 144.

Investors should view this sale as a routine compliance step rather than a firm indication of bearish sentiment. The small volume of shares sold and the lack of any recent selling pattern suggest that the transaction is unlikely to influence the company's stock price or liquidity. The overall impact of the sale is considered neutral, with no significant implications for the company's valuation or market position.

References:
[1] https://www.stocktitan.net/sec-filings/LGND/144-ligand-pharmaceuticals-inc-sec-filing-741c729b6f0c.html